Technology

GSK’s 5-in-1 Meningococcal vaccine shows promise in trial

GSK’s 5-in-1 Meningococcal vaccine shows promise in trial

In March 2023 GSK announced positive headline results from a Phase III trial evaluating its MenABCWY combination vaccine candidate. Assessing safety, tolerability, and immunogenicity, the trial started in August 2020. All primary endpoints were met, and the vaccine...

Exclusive interview with Dr Ike James

Exclusive interview with Dr Ike James

With just weeks to go until the World Vaccine Congress in Washington, we are delighted to continue sharing interviews. In this post, we spoke to Dr Ike James, Head of Technology Transfer at the Medicines Patent Pool. Dr James will participate in the conversation...

Thermostable tuberculosis vaccine meets Phase I goals

Thermostable tuberculosis vaccine meets Phase I goals

Tuberculosis is one of the leading infectious causes of morbidity and mortality across the world. In 2020 it killed 1.5 million people and caused 10 million new infections. It also has a disproportionate case burden of two-thirds in 8 countries. Although there is a...

VIE awards 2023: the final shortlist announced!

VIE awards 2023: the final shortlist announced!

With less than a month to go before we congregate for the World Vaccine Congress in Washington in April, we are pleased to share the organisations and individuals who have progressed to the final shortlist for the VIE Awards.   After successful rounds of submissions...

Will cell-free processes accelerate vaccine development?

Will cell-free processes accelerate vaccine development?

Writing for Nature in March 2023, Carrie Arnold explores the possibilities presented by cell-free processes. Arnold identifies a “growing number of biomanufacturing firms” that are “embracing” a cell-free biosynthesis strategy.   Without relying on yeast or bacteria...

Exclusive interview with Dr Yongjun Sui

Exclusive interview with Dr Yongjun Sui

As we continue our countdown to the World Vaccine Congress in Washington this April we are delighted to share more conversations with some of our fascinating speakers across a range of subjects. In this interview we were pleased to speak to Dr Yongjun Sui of NIH. She...

GSK “delighted” by VRBPAC vote on RSV candidate

GSK “delighted” by VRBPAC vote on RSV candidate

Just one day after Pfizer announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) had voted on its RSV vaccine candidate, GSK announced the results of the Committee’s vote on its candidate. This follows "exceptional” results of a trial...